Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects

NCT02525861 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02525861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02525861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2016
Completion date
July 29, 2020
Enrollment
34 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

alpha1-antitrypsin deficiency